

1 **Title**

2 **Safety and efficacy of two immunization schedules with an inactivated SARS-**
3 **CoV-2 vaccine in adults. A randomized non-inferiority clinical trial.**

4 **Authors**

5 Katia Abarca^{1,2*}, Carolina Iturriaga¹, Marcela Urzúa^{1,3}, Nicole Le Corre¹, Augusto
6 Pineda^{1,4}, Carolina Fernández¹, Angélica Domínguez⁵, Pablo A González^{2,6}, Susan M
7 Bueno^{2,6}, Paulina Donato⁷, Pilar Espinoza⁸, Daniela Fuentes⁹, Marcela González¹⁰,
8 Paula Guzmán¹¹, Paula Muñoz¹², Carlos M Pérez⁸, Marcela Potin^{1,13}, Álvaro Rojas³,
9 José V González-Aramundiz¹⁴, Nicolás MS Gálvez², CoronaVac03CL Study Group, and
10 Alexis M Kalergis^{2,6,15*}.

11 **Affiliations**

12 ¹Departamento de Enfermedades Infecciosas e Inmunología Pediátrica, División de
13 Pediatría, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.

14 ²Millennium Institute on Immunology and Immunotherapy.

15 ³Departamento de Enfermedades Infecciosas del adulto, División de Medicina Interna,
16 School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.

17 ⁴Medicina Física y Rehabilitación, Red de Salud UC Christus, Santiago, Chile

18 ⁵Departamento de Salud Pública, School of Medicine, Pontificia Universidad Católica
19 Chile, Santiago, Chile.

20 ⁶Millennium Institute on Immunology and Immunotherapy. Departamento de Genética
21 Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad
22 Católica de Chile, Santiago, Chile.

23 ⁷Complejo Asistencial Dr. Sótero del Río, Santiago, Chile.

24 ⁸Hospital Félix Bulnes, Facultad de Medicina y Ciencia y Facultad de Ciencias para el
25 Cuidado de la Salud, Universidad San Sebastián, Santiago, Chile.

26 ⁹Hospital Carlos Van Buren, Universidad de Valparaíso, V Región, Chile.

27 ¹⁰Hospital Gustavo Fricke, Universidad de Valparaíso, V Región, Chile.

28 ¹¹Clínica Universidad de Los Andes, Universidad de Los Andes, Santiago, Chile.

29 ¹²Facultad de Medicina Clínica Alemana Universidad del Desarrollo, Santiago, Chile.

30 ¹³Clínica San Carlos de Apoquindo, Red de Salud UC, Santiago, Chile.

31 ¹⁴Departamento de Farmacia, Facultad de Química y de Farmacia, Pontificia
32 Universidad Católica de Chile, Santiago, Chile.

33 ¹⁵Departamento de Endocrinología, Facultad de Medicina, Escuela de Medicina,
34 Pontificia Universidad Católica de Chile, Santiago, Chile.

35 **Keywords:**

36 CoronaVac[®]; Phase 3 clinical trial; SARS-CoV-2; COVID-19; Vaccines; immunization
37 schedules.

38 **Short running title: CoronaVac[®] safety and efficacy in adults by two immunization
39 schedules.**

40 ***Corresponding authors:** Katia Abarca (kabarca@uc.cl/+56996797787) and Alexis M.
41 Kalergis (akalergis@bio.puc.cl/+56223541924); Av. Libertador Bernardo O'Higgins
42 #340, Santiago, Chile.

43 **Research in context**

44 **Evidence before this study**

45 CoronaVac[®] (an inactivated SARS-CoV-2 vaccine) was approved on June 1st, 2021, by
46 the WHO for its use in humans. Sinovac Life Sciences generated this vaccine in China
47 and conducted phase 1/2 trials. Good safety, efficacy, and immunogenicity profiles were
48 reported. The results from this study led to the use of CoronaVac[®] in other countries,
49 such as Brazil, Turkey, and Chile, with phase 3 trials being held on them.

50 **Added-value of this study**

51 This work compares the safety and efficacy of two immunization schedules with
52 CoronaVac[®], with each dose administered two or four weeks after the first dose on
53 healthy Chilean adults. To date, no studies showing the safety and efficacy of these two
54 immunization schedules with CoronaVac[®] in healthy adults in a population other than
55 the Chinese have been published. We show that CoronaVac[®] is safe and prevents
56 hospitalization due to COVID-19 in both immunization schedules. No differences were
57 found in the incidence of adverse events between both schedules, and no related
58 severe adverse events were reported. These results give further insight into the immune
59 response induced by CoronaVac[®] and are relevant when deciding on the immunization
60 schedule chosen for vaccination.

61 **Implications of all the available evidence**

62 The data reported here show that using either immunization schedule with two doses of
63 CoronaVac[®] protects against SARS-CoV-2. The data also indicate that CoronaVac[®]
64 does not induce severe adverse events in either immunization schedule, and the
65 adverse events registered are mild and transient, confirming the safety of this vaccine.

66 **Abstract**

67 **Background:** Several vaccines have been developed to control the COVID-19
68 pandemic. CoronaVac[®] (Sinovac Life Sciences), an inactivated SARS-CoV-2 vaccine,
69 has demonstrated safety and immunogenicity in previous studies, preventing severe
70 COVID-19 cases. We further investigated the safety and efficacy of two immunization
71 schedules of CoronaVac[®] in a non-inferiority trial in healthy adults.

72 **Methods:** This is a multi-center and randomized clinical trial. Healthy adults were
73 enrolled at eight centers in Chile. Participants were randomly assigned to two
74 vaccination schedules, receiving two doses with either 14 (0-14) or 28 (0-28) days
75 between each. 2302 participants were vaccinated. The primary safety and efficacy
76 endpoints were solicited adverse events (AE) within 7 days after each dose and
77 compared the number of cases of SARS-CoV-2 infection 14 days after the second dose
78 between schedules, respectively.

79 **Findings:** The most frequent local AE was pain at the injection site, which was less
80 frequent in participants aged ≥ 60 years. Other local AEs were reported in less than 5%
81 of participants. The most frequent systemic AEs were headache, fatigue, and myalgia.
82 The remaining AEs were minor allergic reactions and fever. Most AEs were mild and
83 transient. There were no significant differences for local and systemic AE between
84 schedules. No anaphylactic reactions or vaccine-related severe AEs were observed. 58
85 COVID-19 cases were confirmed, and all but two of them were mild. No differences
86 were observed in protection between schedules.

87 **Interpretation:** CoronaVac[®] is safe, especially in ≥ 60 years-old participants. Both
88 schedules protected against COVID-19 hospitalizations.

89 **Funding:** MINSAL, Chile, CPC & IMII, Chile.

90 **Background**

91 In March 2020, the COVID-19 pandemic, a disease caused by the severe acute
92 respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared ¹. Two years into this
93 pandemic, more than 250 million cases have been diagnosed worldwide, and more than
94 5 million deaths can be related to COVID-19 ². In Chile, since March 2020, 1.7 million
95 laboratory-confirmed cases have been reported, and more than 38,000 deaths can be
96 related to COVID-19 by December 2021 ³.

97 Initial COVID-19 outbreaks exhibited high morbidity and mortality in individuals over 60
98 years of age or with comorbidities, such as obesity, chronic pulmonary disease, cardiac
99 disease, and immunosuppressed population ^{4,5}. Antiviral drugs or immunomodulators
100 have not been a successful treatment ⁶. Prophylactic strategies with drugs, such as
101 hydroxychloroquine or ivermectin did not show any significant reduction in the risk of
102 SARS-CoV-2 infection ⁷. Other treatments, such as post-exposure type I interferon
103 prophylaxis, are still being evaluated ⁸.

104 Vaccination is an essential prophylactic strategy to prevent pathogen spreading and the
105 disease caused by a viral infection ⁹. Early during the pandemic, the development of
106 vaccines against SARS-CoV-2 was vigorously pursued. Different vaccine platforms
107 were generated to prevent COVID-19, such as mRNA vaccines or viral vector-based
108 vaccines ¹⁰. Among these, CoronaVac[®] is an inactivated vaccine against SARS-CoV-2
109 developed in Vero cells (Sinovac Life Sciences, Beijing, China). Preclinical studies
110 performed in mice, rats, and non-human primates demonstrated that this vaccine was
111 immunogenic and induced anti-SARS-CoV-2 neutralizing antibodies ¹¹. Moreover,
112 partial or complete protection against pneumonia after a viral challenge was shown in

113 primates ¹¹. All these results led to human clinical trials. A phase I/II sequential clinical
114 trial was performed, including 144 and 600 healthy adults aged 18 to 59 years,
115 respectively ¹². Two doses (3 and 6 µg) and two vaccination schedules (two doses
116 separated by either two or four weeks) were evaluated. Results demonstrated that this
117 inactivated vaccine was well tolerated with mild local adverse events after two doses ¹².
118 Although anti-SARS-CoV-2 neutralizing antibodies geometric mean titers (GMT) were
119 lower when compared to convalescent patients, the vaccine induced a significant
120 humoral response with both doses and schedules. A phase 1/2 sequential clinical trial
121 performed in healthy adults aged 60 years and older showed that CoronaVac[®] was safe
122 and well-tolerated in this particular population ¹³. Moreover, the 3 µg dose in the elderly
123 group induced anti-SARS-CoV-2 neutralizing antibodies titers similar to those observed
124 in adults aged 18-59 years. All these findings led to the emergency use of CoronaVac[®]
125 in China and supported the development of a phase 3 study to evaluate the efficacy of
126 this inactivated vaccine ¹⁴.

127 Due to the availability of CoronaVac[®] to the general public in Chile since January 2021,
128 we adapted the initial placebo-controlled phase 3 clinical trial in adults to a non-
129 inferiority clinical trial of two different immunization schedules, with the second dose
130 administered either two (0-14) or four (0-28) weeks after the first one, with a planned 12
131 months of follow-up. This report includes the safety and efficacy of non-inferiority results
132 acquired up to six months after the first dose.

133 **Methods**

134 **Study design and participants**

135 This trial (clinicaltrials.gov NCT04651790) is a multi-center, randomized clinical trial to
136 evaluate two vaccination schedules of CoronaVac[®], the Sinovac inactivated SARS-
137 CoV-2 vaccine, in adults in Chile that included health care workers and community
138 participants recruited at eight sites (six in the Metropolitan Region of Santiago and two
139 in the Valparaiso Region). The study was approved by the sponsoring institution Ethical
140 Committee (Comité Ético Científico Ciencias de la Salud UC, Pontificia Universidad
141 Católica de Chile, ID 200708006), and each Institutional Ethical Committee of the other
142 sites (Comité Ético Científico Universidad de Los Andes, Comité Ético Científico
143 Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Comité Ético
144 Científico Hospital Clínico Félix Bulnes, Comité Ético Científico Servicio de Salud
145 Valparaíso-San Antonio, Comité Ético Científico Servicio de Salud Metropolitano Sur
146 Oriente, Chile), and the Public Health Institute of Chile (ISP Chile, number N^o
147 24204/20). This study was also conducted according to the current Tripartite Guidelines
148 for Good Clinical Practices, the Declaration of Helsinki ¹⁵, and local regulations. An
149 independent data and safety monitoring board reviewed the blinded safety and efficacy
150 data.

151 Written informed consent was obtained from each participant before enrollment. After
152 inclusion and exclusion criteria were met (a complete list of inclusion and exclusion
153 criteria has been published previously ¹⁶), participants were randomly assigned to one
154 of 2 open-label vaccination schedules, with either 14 (0-14) or 28 (0-28) days interval
155 between doses, in a 1:1 ratio.

156 **Aims**

157 The primary safety endpoint was to evaluate the frequency of AE occurring on the first 7
158 days after each dose of the vaccine in each vaccination schedule. The secondary
159 endpoint was to determine the occurrence of SAE and events of special interest in both
160 vaccination schedules during all the study.

161 The primary non-inferiority efficacy endpoint was to evaluate and compare the
162 protection against confirmed SARS-CoV-2 infection of two vaccination schedules,
163 starting two weeks after the second dose. Non-inferiority of 0-14 over 0-28 schedule
164 was defined as a difference in the protection rate within a threshold of 15%. Secondary
165 efficacy endpoints were to compare both vaccination schedules regarding hospitalized
166 cases and deaths within the same period.

167

168 **Procedures**

169 Demographic information, comorbidities, concomitant medications, and nutritional status
170 were registered at enrolment and registered in a paper case report form (CRF) and an
171 electronic CRF (eCRF). Blood samples and nasopharyngeal swabs were obtained for
172 all participants prior to immunization to evaluate past or current SARS-CoV-2 infection.
173 A urine test was performed on all female participants to assess potential pregnancies,
174 an exclusion criterion. Participants were inoculated with 3 µg (600SU) of Coronavac[®]
175 and then kept in observation for 60 min after each dose to evaluate possible adverse
176 events (AE). Immediate AE was defined as reporting the AE within this period. Then,
177 participants, or their representative, if applicable, were instructed to register through a
178 remote application any local and systemic solicited AE for 7 days after each dose and

179 any other AE and concomitant medications until 28 days after the second dose. Non-
180 immediate AEs were defined as those occurring after the first 60 minutes after
181 vaccination. Serious adverse events (SAE), events of special interest (using the priority
182 List of Events of Special Interest in COVID-19 vaccines by Brighton Collaboration)¹⁷,
183 relevant medications (immunosuppressive drugs, transfusions, and other vaccines), and
184 symptoms of SARS-CoV-2 infection were collected throughout the entire study. The
185 system sent daily reminders to all participants until day 28 after the second dose and
186 then weekly until the end of the study. The severity of solicited AE was graded through
187 a numeric scale of 1 to 4, based on the “Toxicity Grading Scale for Healthy Adult and
188 Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials” guide of the Food
189 and Drug Administration of the United States (FDA)¹⁸. The severity of the unsolicited
190 clinical AE was classified through a numeric scale of 1 to 5, based on the “Common
191 Terminology Criteria for Adverse Events - Version 5.0” guide by the United States
192 National Cancer Institute (NCI /NIH)¹⁹. The investigators determined a possible causal
193 association between AE and vaccination according to a classification adapted from the
194 “Uppsala Monitoring Center” of the World Health Organization²⁰. Personnel of the sites
195 reviewed this information for accuracy and completeness and filled an AE or SAE form
196 in the eCRF.

197 To determine the protection against confirmed SARS-CoV-2 infection for each
198 vaccination schedule, participants were followed during the study to identify and register
199 any SARS-CoV-2 infection (COVID-19). The definition of case surveillance for COVID-
200 19 was stated by the WHO²¹. Participants were instructed to register in the remote
201 application and notify the sites through the mail, message, or phone call when they

202 presented at least one of the symptoms for two days (suspicious case definition met). In
203 these cases, a SARS-CoV-2 RT-qPCR was performed. A second sample was collected
204 in the case of a negative RT-qPCR with persisting symptoms, and then a new RT-qPCR
205 was performed. The investigators closely monitored participants who met the confirmed
206 COVID-19 case definition (at least one symptom and a positive RT-qPCR), recording
207 symptoms, severity, start and end dates, therapies, complications, hospitalizations, and
208 admission to the ICU, use of mechanical ventilation, and outcome. The severity of the
209 COVID19 symptoms was classified in 1 to 4 grades based on the guidelines “Toxicity
210 Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive
211 Vaccine Clinical Trials” from the United States Food and Drug Administration (FDA) and
212 the “Common Terminology Criteria for Adverse Events - Version 5.0” guide by the
213 United States National Cancer Institute (NCI /NIH) ^{18,19}. The intensity of the condition
214 was registered using the scale of clinical progression (Score 0 to 10), based on the
215 WHO guidelines ²⁰.

216

217 **Statistical analyses**

218 Baseline characteristics of patients were compared by schedule: categorical variables
219 were expressed as counts and percentages while numerical variables with mean and
220 standard deviation (SD). Categorical variables were analyzed with Chi-square test or
221 Fisher’s exact test; differences in means were tested using Student’s t-test; significance
222 level was set at a more rigorous level of 0.01. The percentage of subjects that
223 presented each solicited AE within the first 7 days was obtained for each schedule. The
224 length of the event was presented as median and quantiles 10 and 90. Incidence of

225 immediate and non-immediate AE was registered. The number of simultaneous non-
226 immediate AEs were expressed as the sum of different AE and are shown as frequency
227 and percentage by dose and schedule. Differences in the incidence of each AE by age
228 were evaluated using Chi-square or Fisher's exact test. The COVID-19 incidence,
229 including only cases occurring 14 days after the second dose, was determined for each
230 schedule and subgroups defined by sociodemographic or clinical characteristics.
231 COVID-19-free survival was estimated using Kaplan-Meier analysis, and schedule
232 curve differences were assessed using the Log Rank test. Cox's regression was used to
233 obtain age and gender-adjusted incidence rate ratios and their 95% confidence interval
234 (CI). The proportional hazards assumption was met. For safety and efficacy, we looked
235 at the non-inferiority of the 0-14 schedule over the 0-28 schedule, with a margin of 15%.
236 Consequently, one-sided statistical tests were used where the rejection of the null
237 hypothesis indicates non-inferiority of the 0-14 schedule over the 0-28 schedule. All
238 statistical analyses were performed using SPSS 17.0.

239

240 **Role of the funding source**

241 The funder had no role in study design, data collection, analysis, interpretation, or report
242 writing.

243

244 **Results**

245 **Demographics and participants**

246 During November 29th, 2020, and April 9th, 2021, a total of 2,302 participants were
247 vaccinated with the first dose of CoronaVac[®]. Of these participants, 1,090 were
248 allocated to the 0-14 schedule and 1,212 to the 0-28 schedule. Safety and efficacy data
249 derived from participants up to October 2021 are reported here, with a median (min-
250 max) of follow-up of 6.5 (0.5-6.7) months for the 0-14 schedule and 6.9 (1.1-7.1) months
251 for the 0-28 schedule. Safety information for 7 days after the first and second doses was
252 available for 2,302 and 2,212 participants, respectively. These data were included in the
253 safety analysis. Moreover, 2,205 participants had clinical information 14 days after the
254 second dose and were included in the efficacy analysis (Figure 1).

255 Demographic characteristics and comorbidities of the population are shown in Table 1.
256 No significant differences were observed between participants who received any of the
257 two vaccination schedules, except a higher proportion of health workers in the 0-14
258 schedule; and a higher BMI and frequency of participants aged over 60 in the 0-28
259 schedule.

260

261 **Safety parameters**

262 During the first 60 minutes after vaccination, 1-2% of participants reported local pain at
263 the administration site. The other AEs were recorded in even lower frequency
264 (Supplementary Table 1). No anaphylactic reactions were observed. After this
265 immediate period, a total of 882 local and 1,919 systemic solicited AEs were reported
266 upon administration of the first dose. These AEs were reported in 32.1% and 41.5% of

267 the vaccinated participants for the 0-14 and 0-28 schedules. A total of 867 local and
268 1395 systemic solicited AE were reported after the second dose. These AEs were
269 reported in 31.2% and 32.9% of the vaccinated participants for the 0-14 and 0-28
270 schedules, respectively (Figure 1 and supplementary table 2). The 0-14 schedule
271 showed no inferiority to the 0-28 schedule ($p < 0.0001$) in the frequency of AEs
272 (Supplementary Table 2).

273 After the first dose, 67.9% of the participants did not report any local AE, 26.6%
274 reported only pain at the inoculation site, 0.9% reported pain and induration, 0.8%
275 reported pain and local pruritus, and 0.6% reported only pruritus. All other combinations
276 were found in less than 0.5% of the participants. After the second dose, 68.8% of the
277 participants did not report any AE, 24.7% reported only pain at the inoculation site, 1.4%
278 reported pain and induration, 0.8% reported pain, induration, and pruritus. All other
279 combinations were found in less than 0.6% of the participants. Majority of the
280 participants who presented any local AE after each dose reported one or two AEs
281 (Supplementary Table 3).

282 After each dose, the most frequent solicited systemic AEs were headache, fatigue, and
283 myalgia, reported in 20-26%, 12-17%, and 11-14% of the participants, respectively. The
284 remaining systemic AEs were reported in less than 10% of the vaccinated participants.
285 Notably, minor allergic reactions and fever were reported by less than 2% and 1% of the
286 vaccinated participants, respectively (Figure 2 and Supplementary Table 2). The
287 number of simultaneous systemic AEs is shown in Supplementary Table 3. The majority
288 of the participants who presented any systemic AE reported one or two simultaneous
289 AE. Most local and systemic AEs were mild, with 0.5% or fewer participants reporting

290 grade 3 AEs after the first dose and 0.6% or less after the second dose. There were no
291 reports of grade 4 AEs (Figure 2). The most frequent local and systemic AEs resolved in
292 a median of 2 days (Supplementary Table 4). When comparing by age group, older
293 participants (≥ 60 years old) showed less incidence of AEs than did younger participants
294 (18-59 years old) (Supplementary Table 5).

295 No vaccine-related SAE occurred, and 60 non-vaccine-related SAEs were reported,
296 including 3 deaths: two sudden deaths, one due to acute myocardial infarction, one
297 month after the second dose (male, between 50 and 60 years old), and other in a
298 patient with a history of hepatic cirrhosis due to alcoholic liver disease, three months
299 after the second dose (male between 60 and 70 years-old). The third death was due to
300 gastric cancer Stage IV diagnosed five months after enrolment (female, between 70 and
301 80 years old). Five pregnancies have been reported in participants of the study, two of
302 them during the first four weeks after the second dose, one twin and one single
303 pregnancy. All had a negative pregnancy test and contraceptive use before each
304 vaccine dose, and these participants are being followed-up by the investigators, with no
305 obstetric nor perinatal complications reported to date. To date, one of the pregnancies
306 concluded with the birth of healthy twins. No other events of special interest have
307 occurred in the study.

308

309 **Vaccine efficacy**

310 Upon 14 days after the administration of the second dose of CoronaVac[®], 58
311 symptomatic and confirmed COVID-19 cases have been registered. The demographic
312 and clinical characteristics of these COVID-19 cases are shown in Table 2. The vast

313 majority of these cases were mild (Score 2) (94.8%), and just two participants were
314 hospitalized. The first one was a male, aged over 60 years, BMI 28.0 (over-weighted),
315 with arterial hypertension and bicuspid aorta. This participant exhibited COVID-19
316 symptoms 32 days after the second dose of a 0-28 schedule and was a confirmed close
317 contact with a COVID-19 case. The participant developed atrial fibrillation and heart
318 failure and required mechanical ventilation (Score 7) for six days and hospitalization for
319 20 days. The second participant is a male, aged over 60 years, BMI of 29.3 (over-
320 weighted), in treatment for hypothyroidism. The second participant exhibited COVID-19
321 symptoms 122 days after the second dose of a 0-28 schedule, and no close contact
322 with other COVID-19 cases. The participant received oxygen by nasal cannula (Score
323 5) for four days and was released after seven days of hospitalization. Both participants
324 exhibited cough, dyspnea, and fatigue for more than seven weeks but ultimately
325 recovered.

326 A total of 34 and 24 cases of COVID-19 were registered in the 0-14 and the 0-28
327 schedule, respectively ($p=0.083$) (Table 2). Both schedules showed a high probability of
328 being COVID-19-free: 96.7% (0-14) and 97.9% (0-28) (non-inferiority p -value <0.001). A
329 Kaplan-Meier analysis showed that the probability of 0.98 for being COVID-19-free is
330 achieved at day 91 for the 0-14 schedule and at day 133 for the 0-28 schedule.
331 Although the COVID-19 incidence rate showed a slightly higher curve for the 0-14 than
332 the 0-28 schedule, this difference was not statistically significant (log-rank test, p -value
333 = 0.071) (Figure 3). The 0-14 schedule showed non inferiority to the 0-28 schedule
334 when comparing COVID-19 incidence in different subpopulations defined by
335 demographic and clinical characteristics (Supplementary Table 6).

336 The incidence of COVID-19 cases tends to be higher in health care workers compared
337 with the general population for both immunization schedules (for 0-14 schedule, cases
338 presented in 4.5 v/s 2.4% and for 0-28 in 3.1 v/s 1.7%); but these differences were not
339 statistically significant. Also, the infection rate tends to be lower in ≥ 60 years old
340 participants, but the significance level set for this analysis was not achieved ($p=0.024$).
341 No statistical differences were observed in the frequency of COVID-19 cases between
342 sex and comorbidities.

343 Discussion

344 This non-inferiority trial demonstrated that the virus inactivated, CoronaVac[®], given in
345 two doses, with a 14 or 28 days interval between each dose, was safe, well-tolerated,
346 and protective. A six-month surveillance showed a non-inferiority of the 0-14 over the 0-
347 28 schedule in solicited AEs and confirmed COVID-19 cases. These results further
348 support the safety and protective capacity for massive use of the Coronavac[®] vaccine in
349 adults, including participants older than 60 years old.

350 Regarding the safety of CoronaVac[®], no vaccine-associated SAEs nor events of special
351 interest were reported up until six months of follow-up in this cohort of over 2,300 adults.
352 During phase III trials with adenovirus and mRNA-based vaccine formulations, four and
353 one SAEs were associated with each vaccine, respectively ^{22,23}. However, post-
354 approval reports showed an increased incidence of vaccine-induced thrombotic
355 thrombocytopenia, particularly for the adenovirus-based vaccine prototypes ²³.
356 Moreover, cases of vaccine-related myocarditis were observed in adolescents and
357 young adults vaccinated with mRNA-based vaccine ²⁴.

358 CoronaVac[®] showed a low reactogenicity profile, with around 30% of vaccinated
359 participants reporting local pain, less than 1% fever, and no significant allergic
360 reactions. In this line, AEs reported on the phase III trials with CoronaVac[®] performed in
361 Turkey and Brazil were primarily mild and self-limited ^{25,26}. The low reactogenicity profile
362 of CoronaVac[®] contrasts with the relatively high incidence of local and systemic AEs
363 reported post-vaccination for other vaccine platforms, such as mRNA and adenoviral
364 vectors, with pain observed in 50-80%, fever in 16-51%, fatigue up to 70%, and
365 myalgias up to 60% of the participants ^{22,27}.

366 Regarding the vulnerable population, 30% of the enrolled participants in this study were
367 ≥ 60 years old, and 45% had chronic conditions. Lower frequencies of post-vaccination
368 AEs were observed for the older age cohort compared to the younger participants.
369 Consistently with this notion, only one elderly subject developed a fever after
370 vaccination, a condition that could escalate in older people. Concordantly, in a
371 nationwide cross-sectional study for side effects of CoronaVac[®] performed in Turkey,
372 younger age was a risk factor associated with an discrete increase of vaccine side
373 effects ²⁶. These features contribute to the confidence for the massive administration of
374 this vaccine, especially in the most vulnerable populations.

375 Although the study design does not allow calculation of true efficacy for the vaccine due
376 to the absence of a placebo arm, we demonstrate that in a scenario of high viral
377 circulation ³, the vast majority of COVID-19 cases developed by vaccinated participants
378 were only mild. Only two participants aged over 60 years required hospitalizations, and
379 no deaths due to COVID-19 occurred as part of the study ²⁸. These data are consistent
380 with the immunogenicity results reported in Chile so far, showing that CoronaVac[®]
381 induces the secretion of specific IgG against the S1-RBD with neutralizing capacity, as
382 well as the activation of T cells specific for SARS-CoV-2 antigens ¹⁶. Moreover, the wide
383 use of this vaccine in the Chilean population was monitored by de Ministry of Health
384 and has shown an effectiveness of 67,7% to prevent symptomatic COVID-19 cases and
385 more than 85% to prevent severe COVID-19 cases and deaths due to SARS-CoV-2
386 infection ²⁹.

387 Comparing the protective efficacy of two different vaccination schedules (0-14 v/s 0-28)
388 against SARS-CoV-2 infection could help health authorities make evidence-based

389 decisions for massive immunization against COVID-19. A more rapid schedule could
390 lead to faster vaccination of the population, which could be relevant during an epidemic.
391 It is essential to evaluate differences regarding immunogenicity, efficacy, and
392 effectiveness between an accelerated schedule versus a standard four-week interval.
393 Two previous reports with this vaccine showed a more robust immune response for the
394 0-28 schedule than for the 0-14 schedule ¹². A phase I/II trial held in China showed
395 higher neutralizing antibodies seroconversion rates for the 0-28 schedule compared to
396 the 0-14 schedule ¹².

397 Regarding efficacy, although we observed a trend toward higher efficacy for the 0-28
398 schedule compared to the 0-14 schedule, these differences were not statistically
399 significant. A previous study that evaluated the efficacy of CoronaVac[®] in a 0-14
400 schedule demonstrated that this parameter was higher in participants who received the
401 two doses with an interval of over 21 days ²⁵. An explanation for this apparent
402 discrepancy is that in our study, the group included in the 0-14 schedule consisted
403 mainly of healthcare workers, which are usually more exposed to the virus and therefore
404 have higher risks of infection. Further studies with a more homogeneous population
405 could contribute to addressing these questions.

406 Older age is a described risk factor related to COVID-19 severity ³⁰, also observed in
407 our study. Here, the two severe cases reported occurred just in older participants.
408 However, the frequency of cases tended to be lower in this age group. This could be
409 related to the most strict protective measures taken in this population and their lower
410 mobility during the time of the study.

411 After a six-month follow-up, two doses of CoronaVac[®] demonstrated to be well-
412 tolerated, safe, and protective, particularly in a high-risk population. Regarding
413 vaccination schedules, our data suggest that both a 0-14 and a 0-28 schedule show
414 equivalent safety and efficacy results for this vaccine.

415 **Funding:**

416 The Ministry of Health, Government of Chile, supported the funding of the
417 CoronaVac03CL Study; The Confederation of Production and Commerce (CPC), Chile,
418 supported the funding of the CoronaVac03CL Study; The Millennium Institute on
419 Immunology and Immunotherapy, ANID - Millennium Science Initiative Program
420 ICN09_016 (former P09/016-F) supports SMB, KA, PAG, and AMK; The Innovation
421 Fund for Competitiveness FIC-R 2017 (BIP Code: 30488811-0) supports SMB, PAG,
422 and AMK. SINOVAC contributed to this study with the investigational vaccine and
423 placebo, and experimental reagents.

424

425 **Declaration of interest:**

426 All authors declare no conflict of interest.

427

428 **Author contributions:**

429 **Conceptualization:** KA, PAG, SMB, JVG, AMK,

430 **Methodology:** KA, CI, MU, AP, CF, PD, PE, DF, MG, PG, PM, CMP, MP, AR.

431 **Investigation:** KA, CI, MU, AP, CF, PD, PE, DF, MG, PG, PM, CMP, MP, AR.

432 **Funding acquisition:** SMB, AMK.

433 **Project administration:** KA, PAG, SMB, AMK.

434 **Supervision:** KA, PAG, SMB, AMK.

435 **Writing – original draft:** KA, CI, MU, NLC, AD.

436 **Writing – review & editing:** KA, SMB, PAG, NMSG, AMK.

437

438 **Acknowledgments**

439 We would like to thank the Ministry of Health, Government of Chile; Ministry of Science,
440 Technology, Knowledge, and Innovation, Government of Chile; and The Ministry of
441 Foreign Affairs, Government of Chile and the Chilean Public Health Institute (ISP). We
442 also thank the Vice Presidency of Research (VRI), the Direction of Technology Transfer
443 and Development (DTD), the Legal Affairs Department (DAJ) of the Pontificia
444 Universidad Católica de Chile. We are also grateful to the Administrative Directions of
445 the School of Biological Sciences and the School of Medicine of the Pontificia
446 Universidad Católica de Chile for their administrative support. Special thanks to the
447 independent data safety monitoring committee (members in the Supplementary
448 Appendix (SA)) for their oversight and to the participants enrolled in the study for their
449 participation and commitment to this trial. Members of the CoronaVac03CL Study Team
450 are listed in the SA.

451

452 **Data and materials availability:**

453 All analyzed and raw data (masked to protect the information of volunteers) is available
454 upon reasonable request to the corresponding authors through email after the
455 publication of this article. A signed data access agreement will be requested to share
456 the data. The study protocol is also available online and annexed to this article.

457 **References**

- 458 1 Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. *Acta Biomed*
459 2020; **91**: 157–60.
- 460 2 WHO. Weekly Epidemiological Update on COVID-19. *World Heal Organ* 2020; :
461 1;4.
- 462 3 Ministerio de Salud G de C. Informe Epidemiológico N°164 Enfermedad por
463 SARS-CoV-2. 2021. [https://www.minsal.cl/wp-content/uploads/2021/12/Informe-](https://www.minsal.cl/wp-content/uploads/2021/12/Informe-Epidemiológico-164.pdf)
464 [Epidemiológico-164.pdf](https://www.minsal.cl/wp-content/uploads/2021/12/Informe-Epidemiológico-164.pdf) (accessed Jan 31, 2022).
- 465 4 Booth A, Reed AB, Ponzio S, *et al.* Population risk factors for severe disease and
466 mortality in COVID-19: A global systematic review and meta-analysis. *PLoS One*
467 2021; **16**: e0247461.
- 468 5 Zhou F, Yu T, Du R, *et al.* Clinical course and risk factors for mortality of adult
469 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*
470 (*London, England*) 2020; **395**: 1054–62.
- 471 6 Vijayvargiya P, Esquer Garrigos Z, Castillo Almeida NE, Gurram PR, Stevens
472 RW, Razonable RR. Treatment Considerations for COVID-19: A Critical Review
473 of the Evidence (or Lack Thereof). *Mayo Clin Proc* 2020; **95**: 1454–66.
- 474 7 Bartoszko JJ, Siemieniuk RAC, Kum E, *et al.* Prophylaxis against covid-19: living
475 systematic review and network meta-analysis. *BMJ* 2021; **373**: n949.
- 476 8 Lee AC, Jeong Y, Lee S, *et al.* Nasopharyngeal Type-I Interferon for Immediately
477 Available Prophylaxis Against Emerging Respiratory Viral Infections. *Front*
478 *Immunol* 2021; **12**: 660298.
- 479 9 Rodrigues CMC, Plotkin SA. Impact of Vaccines; Health, Economic and Social

- 480 Perspectives. *Front Microbiol* 2020; **11**: 1526.
- 481 10 Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. SARS-
482 CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. *NPJ*
483 *vaccines* 2021; **6**: 28.
- 484 11 Gao Q, Bao L, Mao H, *et al.* Development of an inactivated vaccine candidate for
485 SARS-CoV-2. *Science* 2020; **369**: 77–81.
- 486 12 Zhang Y, Zeng G, Pan H, *et al.* Safety, tolerability, and immunogenicity of an
487 inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a
488 randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet*
489 *Infect Dis* 2021; **21**: 181–92.
- 490 13 Wu Z, Hu Y, Xu M, *et al.* Safety, tolerability, and immunogenicity of an inactivated
491 SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a
492 randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet*
493 *Infect Dis* 2021; **21**: 803–12.
- 494 14 Staff R. Sinovac's coronavirus vaccine candidate approved for emergency use in
495 China –source. 2020. [https://www.reuters.com/article/us-health-coronavirus-](https://www.reuters.com/article/us-health-coronavirus-china-vaccines-idUSKBN25O0Z3)
496 [china-vaccines-idUSKBN25O0Z3](https://www.reuters.com/article/us-health-coronavirus-china-vaccines-idUSKBN25O0Z3) (accessed Jan 31, 2022).
- 497 15 Valdespino Gómez JL, García García MDL. Declaración de Helsinki. *Gac. Med.*
498 *Mex.* 2001; **137**: 391.
- 499 16 Bueno SM, Abarca K, González PA, *et al.* Safety and Immunogenicity of an
500 Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile. *Clin*
501 *Infect Dis* 2021; : 2021.03.31.21254494.
- 502 17 VACCines SP for E. D2.3 Priority List of Adverse Events of Special Interest:

- 503 COVID-19. 2020 [https://brightoncollaboration.us/wp-](https://brightoncollaboration.us/wp-content/uploads/2020/06/SPEAC_D2.3_V2.0_COVID-19_20200525_public.pdf)
504 [content/uploads/2020/06/SPEAC_D2.3_V2.0_COVID-19_20200525_public.pdf](https://brightoncollaboration.us/wp-content/uploads/2020/06/SPEAC_D2.3_V2.0_COVID-19_20200525_public.pdf)
505 (accessed Jan 31, 2022).
- 506 18 U. S. Department of Health and Human Services, Services USD of H and H,
507 Administration F and D, Research C for BE and. Toxicity Grading Scale for
508 Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical
509 Trials. *Guid Ind* 2007. <http://www.fda.gov/cber/guidelines.htm>. (accessed Aug 14,
510 2019).
- 511 19 National Cancer Institute. Common Terminology Criteria for Adverse Events (
512 CTCAE) version 5.0. *NIH Publ* 2017.
- 513 20 WHO-UM. The use of the WHO-UMC system for standardized case causality
514 assessment. Uppsala Uppsala Monit. Cent. 2014.
- 515 21 WHO. Public Health Surveillance for COVID-19. *Interim Guid* 2020; : 253–78.
- 516 22 Polack FP, Thomas SJ, Kitchin N, *et al*. Safety and Efficacy of the BNT162b2
517 mRNA Covid-19 Vaccine. *N Engl J Med* 2020; **383**: 2603–15.
- 518 23 Voysey M, Clemens SAC, Madhi SA, *et al*. Safety and efficacy of the ChAdOx1
519 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four
520 randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* 2021.
521 DOI:10.1016/S0140-6736(20)32661-1.
- 522 24 Barda N, Dagan N, Ben-Shlomo Y, *et al*. Safety of the BNT162b2 mRNA Covid-
523 19 Vaccine in a Nationwide Setting. *N Engl J Med* 2021; **385**: 1078–90.
- 524 25 Palacios R, Batista AP, Albuquerque CSN, *et al*. Efficacy and Safety of a COVID-
525 19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV

- 526 Study. *SSRN Electron J* 2021. DOI:10.2139/ssrn.3822780.
- 527 26 Tanriover MD, Doğanay HL, Akova M, *et al.* Efficacy and safety of an inactivated
528 whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind,
529 randomised, placebo-controlled, phase 3 trial in Turkey. *Lancet* 2021; **398**: 213–
530 22.
- 531 27 Zhu F-C, Li Y-H, Guan X-H, *et al.* Safety, tolerability, and immunogenicity of a
532 recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,
533 open-label, non-randomised, first-in-human trial. *Lancet (London, England)* 2020;
534 **395**: 1845–54.
- 535 28 Duarte LF, Gálvez NMS, Iturriaga C, *et al.* Immune Profile and Clinical Outcome
536 of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2
537 Vaccine. *Front Immunol* 2021; **12**: 742914.
- 538 29 Jara A, Undurraga EA, González C, *et al.* Effectiveness of an Inactivated SARS-
539 CoV-2 Vaccine in Chile. *N Engl J Med* 2021; **385**: 875–84.
- 540 30 Ho FK, Petermann-Rocha F, Gray SR, *et al.* Is older age associated with COVID-
541 19 mortality in the absence of other risk factors? General population cohort study
542 of 470,034 participants. *PLoS One* 2020; **15**: e0241824.
- 543
- 544

545

546 **Figure 1. Study design for this Phase 3 trial with two different immunization**
547 **schedules as of October 2021.** This study aims to characterize the safety and efficacy
548 elicited by two immunization schedules with CoronaVac[®], with each dose separated by
549 either 14 or 28 days.

550

551 **Figure 2. Frequency and severity of local and systemic adverse events by**
552 **schedule and dose.** Frequencies and severity grades are shown in percentage. (A)
553 Local adverse events. (B & C) Systemic adverse events.

554

555 **Figure 3. Cumulative incidence of COVID-19 infection by immunization schedule.**
556 Cumulative incidence for COVID-19 infections 14 days after administration of the
557 second dose in two vaccination schedules (0-14 [solid line] and 0-28 [dashed line]). The
558 X-axis shows days elapsed from the second dose to the event or censoring time.
559 Censoring was set at the date of the third vaccination, retirement from the study, or
560 reaching six months after the second dose, whichever occurred first.

561

562 **Table 1.** Clinic and demographic characteristics of the study population at baseline.

	Total	Schedule 0-14	Schedule 0-28	p value (a)
	(n=2302)	(n=1090)	(n=1212)	
Age; n (%)				0.001
18-59	1616 (70.2)	800 (73.4)	816 (67.3)	
60-98	686 (29.8)	290 (26.6)	396 (32.7)	
Sex; n (%)				0.015
Female	1212 (52.6)	603 (55.3)	609 (50.2)	
BMI; mean ± SD	26.9 ± 4.5	26.6 ± 4.4	27.1 ± 4.6	0.003
Ethnicity; n (%)				0.128
Hispanic or Latino	2294 (99.7)	1083 (99.4)	1211 (99.9)	
Chilean native	4 (0.2)	3 (0.3)	1 (0.1)	
Asian	3 (0.1)	3 (0.3)	0 (0.0)	
Black	1 (0.0)	1 (0.1)	0 (0.0)	
Health workers; n (%)				<0.001
Yes	759 (33.0)	459 (42.1)	300 (24.8)	
Comorbidities; n (%)				
≥1	1042 (45.3)	487 (44.7)	555 (45.8)	0.580
Comorbidities; n (%)				
Cardiovascular disease	34 (1.5)	14 (1.3)	20 (1.7)	0.468
Asthma and COPD*	148 (6.4)	83 (7.6)	65 (5.4)	0.028
Diabetes	117 (5.1)	44 (4.0)	73 (6.0)	0.030
Insulin resistance	180 (7.8)	85 (7.8)	95 (7.8)	0.967
Hypothyroidism	248 (10.8)	135 (12.4)	113 (9.3)	0.018
Arterial hypertension	415 (18.0)	174 (16.0)	241 (19.9)	0.015
Allergic rhinitis	300 (13.0)	137 (12.6)	163 (13.4)	0.531
Thyroid disease	251 (10.9)	136 (12.5)	115 (9.5)	0.022
Obesity	478 (20.8)	205 (18.8)	273 (22.5)	0.028
Dyslipidaemia	43 (1.9)	18 (1.7)	25 (2.1)	0.467

563

564

565 **Table 2.** Characteristics of COVID-19 positive participants by immunization schedule.

	Total (n=58)	Schedule 0-14 (n=34)	Schedule 0-28 (n=24)
Age in years, n (%)			
18-59	48 (82.8)	29 (85.3)	19 (79.2)
60-98	10 (17.2)	5 (14.7)	5 (20.8)
Sex, n (%)			
Female	31 (53.4)	18 (52.9)	13 (54.2)
Clinical score, n (%)			
2 (symptomatic, independent)	55 (94.8)	33 (97.1)	22 (91.7)
3 (symptomatic, assistance needed)	1 (1.7)	0 (0.0)	1 (4.1)
5 (hospitalized, oxygen by mask or nasal prongs)	1 (1.7)	1 (2.9)	0 (0.0)
7 (intubation and mechanical ventilation)	1 (1.7)	0 (0.0)	1 (4.1)
Severity criteria, n (%)			
Hospitalizations	2 (3.4)	1 (2.9)	1 (4.1)
UCI admissions	1 (1.7)	0 (0.0)	1 (4.1)
Deaths	0 (0.0)	0 (0.0)	0 (0.0)
Health setting workers, n (%)			
Yes	28 (48.3)	19 (55.9)	9 (37.5)
Comorbidities, n (%)			
≥1	26 (44.8)	14 (41.2)	12 (50.0)
Comorbidities, n (%)			
Cardiovascular disease	4 (6.9)	2 (5.9)	2 (8.3)
Asthma and COPD*	6 (10.3)	3 (8.8)	3 (12.5)
Diabetes	3 (5.2)	2 (5.9)	1 (4.2)
Insulin resistance	5 (8.6)	1 (2.9)	4 (16.7)
Arterial hypertension	14 (24.1)	9 (26.5)	5 (20.8)
Allergic rhinitis	7 (12.1)	3 (8.8)	4 (16.7)
Thyroid disease	3 (5.2)	3 (8.8)	0 (0.0)
Obesity	14 (24.1)	5 (14.7)	9 (37.5)
Dyslipidaemia	0 (0.0)	0 (0.0)	0 (0.0)

* COPD: chronic obstructive pulmonary disease

Data are presented as frequency and percentage of the total number of cases in each subgroup and were compared with Chi-square test or Fisher exact test; all p values were higher than 0.05.





